Projects per year
Personal profile
Personal profile
As one of well-known principles, it has become Dr. Zhou’s belief the earlier statistics gets involved in Drug Research & Development, the better outcome will be. Over years of work, Dr. Zhou has incorporated the principles and techniques of statistics as a discipline into the full cycle of Drug R&D, including the successful market applications of oncology immunotherapy Keytruda and cervical cancer vaccine Gardasil, as well as the publication of several articles in top medical journals.
Graduated with a B.S. in Statistics from Nankai University in 2006 and a Ph.D. from The George Washington University in 2011, Dr. Zhou has enriched his comprehension of statistics via a unique career pathway in Drug R&D. His internship at FDA and postdoc research experiences at drug toxicity (Ohio State University) and clinical trials data analyses (Duke University) have opened his door to Drug R&D. He later joined MSD (2015-2018) as a statistician for Phase I & III Drug Development Projects in Oncology and Vaccine areas, including successful filings of Keytruda and Gardasil.
Bearing the open problem regarding a more effective approach to Drug R&D, he went to Sun Yat-Sen university for a grand theory on the full chain Drug R&D (from lab discovery all the way to post-market surveillance) with focuses on the usage of machine learning and causal inference. His teaching on core statistical courses on both undergraduate and graduate levels, including machine learning, has promoted his pursuit on the fundamentals of machine learning via equivariance criterion. Meanwhile, he has conducted several research projects on medical data with the extensive usage of optimal treatment regime methods in precision medicine, including a methodology development project on oncology clinical trials.
During the Covid 19 pandemic, he has participated in several Covid-19 vaccine development projects as the independent statistician, where he has witnessed successes and failures and gained first-hand-on experiences over vaccine development, especially on the early-stage planning. Those experiences have further stimulated him into the development of a statistical theory over the full chain Drug R&D.
Research interests
- Statistics in Drug Research & Development
- Applications and Fundamentals of Machine Learning
- Statistical Inference with a Special Focus on the Equivariance Criterion
- Methodology Development on Medical Data Analyses
- Precision Medicine
Experience
Research Intern Jun 2009 - Aug 2009
U.S Food and Drug Administration, Silver Spring, Maryland
- Worked on two projects on clinical trials in oncology setting with oncology biologics group
- Explored the potential informativeness of censorings in progression-free survival (PFS) due to loss-to-follow- up
- Studied comparison-level (group-wise) correlation vs. patient-level (individual) correlation
Postdoctoral Researcher Oct 2011 – Jul 2013
Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio
- Applied random forests method to analyze high dimensional data for a pharmaceutical classification project of toxicity of chemical compounds
- Leveraged nonparametric methods to improve accuracy and introduced dimension reduction
- Developed weight-of-evidence approaches to estimate and detect uncertainties in predictions
Postdoctoral Associate Aug 2013 – Aug 2014
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC
- Worked on prostate cancer trials data analysis
- Developed related methodologies in survival analysis
Senior Scientist Jan 2015 – Apr 2018
Biostatistics and Research Decision Sciences – Asia & Pacific, Merck Research Laboratory, Beijing, China
- Worked on Phase I & III Drug Development Projects in CV, Oncology and Vaccine areas: Authoring protocols, Conducting Analysis & Report Activities and Supporting Publications
- HPV vaccine Gardasil in mid-aged women and men
- Phase I Study of Pembrolizumab in Chinese Subjects with Non-Small-Cell Lung Cancer
- Diabetes
- Conducted research on Multiple Region Clinical Trial
Associate Professor/Lecturer Apr 2018 – May 2023
Department of Statistics, School of Mathematics, Sun Yat-Sen University
- Taught undergraduate and graduate courses
- Mathematical Statistics, Multivariate Statistics, Machine Learning, Complex Data Analysis
- Conducted Academic Research
- Statistical Inference: Equivariance Principle and Its Usage in Linear Model and Multivariate Analysis
- Precision Medicine: Big Data Analysis and Optimal Treatment Regime
- Survival Analysis: A Novel Statistical Theory and Its applications on Oncology Clinical Trials
- Privacy and Confidentiality Protection and Its Implications in Design and Analysis
Independent Unblinded Statistician Apr 2020 - Feb 2023
- Participated in Covid-19 Vaccine Development and Provided DSMB Statistical Analysis Reports
- Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial & Phase II Clinical Trial (NCT04961359)
- SARS-CoV-2 mRNA Vaccine Phase I Clinical Trial, Phase Ib Clinical Trial & Phase II Clinical Trial (NCT05364047)
- Recombinant New Coronavirus Fusion Protein Vaccine Phase I Clinical Trial & Phase II Clinical Trial (NCT04445194)
- Participated in Oncology Medicine Development and Provided iDMC Statistical Analysis Reports
- Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy (NCT04555304)
Assistant Professor/Adjunct Associate Researcher June 2023 – Present
Academy of Pharmacy, Xi'an Jiaotong-Liverpool University
- Teaching undergraduate and graduate biostat courses
- Conducting Academic Research
- Statistical Inference: Equivariance Principle and Its Usage in Linear Model and Multivariate Analysis
- Clinical Trial Data Modeling and Analysis: A Novel Statistical Theory and Its applications on Oncology Clinical Trials
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Statistics, The George Washington University
Award Date: 31 Aug 2011
Bachelor, Statistics, Nankai University
Award Date: 31 Jul 2006
Person Types
- Staff
Fingerprint
Collaborations and top research areas from the last five years
Projects
- 2 Active
-
Jiangsu Province Higher Education Key Laboratory of Cell Therapy Nanoformulation (Construction)
Ruan, G., Lee, M. H., Wu, Q., Lu, T., Xu, P., Loo, S., Sun, Y., Kam, A., Liu, X., Wen, X., Zhang, J., Wang, M., Xu, M., Cheng, K., Zhang, X., Song, J., Guo, B., Wang, Y., Wang, J., Wu, S., Yang, J., Fu, L., Zhang, J., Qiao, Y., Chen, Y., Li, T., Huang, D., Gu, J., Zhan, T., Wan, Y., He, Z., Cheng, Y., Leng, J., Qi, M., Ho, J., Sun, Y., Zhang, N., Soe, H. M. S. H., Ling, C. & Zhou, H.
1/07/24 → 30/06/27
Project: Governmental Research Project
-
A DUAL COX MODEL THEORY AND ITS APPLICATIONS IN ONCOLOGY
1/01/24 → 31/12/26
Project: Internal Research Project
Research output
- 11 Article
-
Deep Phenotyping and Prediction of Long-term Cardiovascular Disease: Optimized by Machine Learning
Zhuang, X. D., Tian, T., Liao, L. Z., Dong, Y. H., Zhou, H. J., Zhang, S. Z., Chen, W. Y., Du, Z. M., Wang, X. Q. & Liao, X. X., Jun 2022, In: Canadian Journal of Cardiology. 38, 6, p. 774-782 9 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Citations (Scopus) -
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
Maldonado, I., Plata, M., Gonzalez, M., Correa, A., Nossa, C., Giuliano, A. R., Joura, E. A., Ferenczy, A., Ronnett, B. M., Stoler, M. H., Jin Zhou, H., Joshi, A., Das, R., Bautista, O., Group, T., Luxembourg, A., Saah, A. & Buchwald, U. K., 2022, In: Human Vaccines and Immunotherapeutics. 18, 5, 2078626.Research output: Contribution to journal › Article › peer-review
Open Access16 Citations (Scopus) -
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial
Goldstone, S. E., Giuliano, A. R., Palefsky, J. M., Lazcano-Ponce, E., Penny, M. E., Cabello, R. E., Moreira, E. D., Baraldi, E., Jessen, H., Ferenczy, A., Kurman, R., Ronnett, B. M., Stoler, M. H., Bautista, O., Das, R., Group, T., Luxembourg, A., Zhou, H. J. & Saah, A., Mar 2022, In: The Lancet Infectious Diseases. 22, 3, p. 413-425 13 p.Research output: Contribution to journal › Article › peer-review
Open Access67 Citations (Scopus) -
Identification of Novel Phenotypes Correlated with CKD: A Phenotype-Wide Association Study
Lin, Y., Kong, J., Tian, T., Zhong, X., Zhang, S., Zhou, H., Xiong, Z., Zhao, J., Huang, Y., Liu, M., Dong, Y., Zheng, J., Diao, X., Wu, J., Qin, H., Hu, Y., Wang, X., Zhuang, X. & Liao, X., 2022, In: International Journal of Medical Sciences. 19, 13, p. 1920-1928 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Ma, Y., Fang, W., Zhang, Y., Yang, Y., Hong, S., Zhao, Y., Xie, S., Ge, J., Zhou, H. J., Zhao, H. & Zhang, L., 1 Aug 2020, In: Oncologist. 25, 8, p. 650-e1145Research output: Contribution to journal › Article › peer-review
Open Access14 Citations (Scopus)
Activities
- 3 Participating in an event e.g. a conference, workshop, …
-
The Shanghai Biostatistics Forum
Haojin Zhou (Participant)
12 Dec 2024Activity: Participating in or organising an event › Participating in an event e.g. a conference, workshop, …
-
2024数据科学理论与应用联合会议
Haojin Zhou (Participant)
22 Nov 2024 → 24 Nov 2024Activity: Participating in or organising an event › Participating in an event e.g. a conference, workshop, …
-
The 2nd Joint Conference on Statistics and Data Science in China
Haojin Zhou (Participant)
12 Jul 2024 → 14 Jul 2024Activity: Participating in or organising an event › Participating in an event e.g. a conference, workshop, …